Ultimovacs Future Growth
Future criteria checks 2/6
Ultimovacs is forecast to grow earnings and revenue by 30.7% and 40.7% per annum respectively. EPS is expected to grow by 83.3% per annum. Return on equity is forecast to be -27.8% in 3 years.
Key information
30.7%
Earnings growth rate
83.3%
EPS growth rate
| Biotechs earnings growth | 37.0% |
| Revenue growth rate | 40.7% |
| Future return on equity | -27.8% |
| Analyst coverage | Low |
| Last updated | 27 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -110 | -110 | -110 | 1 |
| 12/31/2025 | 87 | -72 | -80 | -79 | 1 |
| 12/31/2024 | N/A | -146 | -193 | -180 | 1 |
| 6/30/2024 | N/A | -179 | -180 | -180 | N/A |
| 3/31/2024 | N/A | -178 | -199 | -199 | N/A |
| 12/31/2023 | N/A | -189 | -190 | -190 | N/A |
| 9/30/2023 | N/A | -204 | -197 | -197 | N/A |
| 6/30/2023 | N/A | -186 | -196 | -196 | N/A |
| 3/31/2023 | N/A | -165 | -159 | -159 | N/A |
| 12/31/2022 | N/A | -168 | -168 | -168 | N/A |
| 9/30/2022 | N/A | -148 | -152 | -152 | N/A |
| 6/30/2022 | N/A | -153 | -145 | -145 | N/A |
| 3/31/2022 | N/A | -168 | -142 | -142 | N/A |
| 12/31/2021 | N/A | -165 | -126 | -126 | N/A |
| 9/30/2021 | N/A | -138 | -105 | -105 | N/A |
| 6/30/2021 | N/A | -126 | -102 | -102 | N/A |
| 3/31/2021 | N/A | -124 | -110 | -105 | N/A |
| 12/31/2020 | N/A | -121 | -114 | -108 | N/A |
| 9/30/2020 | N/A | -121 | -114 | -108 | N/A |
| 6/30/2020 | N/A | -108 | -102 | -97 | N/A |
| 3/31/2020 | N/A | -77 | -80 | -79 | N/A |
| 12/31/2019 | N/A | -61 | -63 | -63 | N/A |
| 9/30/2019 | N/A | -48 | -59 | -59 | N/A |
| 6/30/2019 | N/A | -48 | -57 | -56 | N/A |
| 3/31/2019 | N/A | -59 | -55 | -55 | N/A |
| 12/31/2018 | N/A | -55 | -51 | -50 | N/A |
| 9/30/2018 | N/A | -50 | -46 | -45 | N/A |
| 6/30/2018 | N/A | -42 | -38 | -38 | N/A |
| 3/31/2018 | N/A | -35 | N/A | -32 | N/A |
| 12/31/2017 | N/A | -33 | N/A | -27 | N/A |
| 12/31/2016 | N/A | -29 | N/A | -31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ULTIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ULTIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ULTIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ULTIO's revenue (40.7% per year) is forecast to grow faster than the UK market (3.7% per year).
High Growth Revenue: ULTIO's revenue (40.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ULTIO is forecast to be unprofitable in 3 years.